{"id":325,"date":"2025-04-27T03:34:42","date_gmt":"2025-04-27T03:34:42","guid":{"rendered":"https:\/\/blog.adlington.fr\/index.php\/2025\/04\/27\/autorisation-pour-un-nouveau-traitement-contre-le-cancer\/"},"modified":"2025-04-27T03:34:42","modified_gmt":"2025-04-27T03:34:42","slug":"autorisation-pour-un-nouveau-traitement-contre-le-cancer","status":"publish","type":"post","link":"https:\/\/blog.adlington.fr\/index.php\/2025\/04\/27\/autorisation-pour-un-nouveau-traitement-contre-le-cancer\/","title":{"rendered":"Autorisation pour un nouveau traitement contre le cancer"},"content":{"rendered":"<blockquote><p>\u00ab&nbsp;Jusqu\u2019\u00e0 maintenant, la FDA approuvait des th\u00e9rapies contre le cancer en fonction de l\u2019organe touch\u00e9 initialement, comme par exemple le poumon ou le sein&nbsp;\u00bb, a expliqu\u00e9 le docteur Richard Pazdur, directeur par int\u00e9rim des produits h\u00e9matologiques et oncologiques au centre d\u2019\u00e9valuation des m\u00e9dicaments de la FDA. \u00ab&nbsp;Nous avons d\u00e9sormais approuv\u00e9 un traitement sur la base de biomarqueurs de la tumeur et non de l\u2019organe affect\u00e9&nbsp;\u00bb<br \/>\n\u2014 Read on <a href=\"https:\/\/www.lemonde.fr\/medecine\/article\/2017\/05\/24\/feu-vert-pour-un-nouveau-traitement-anti-cancer_5132830_1650718.html\">www.lemonde.fr\/medecine\/article\/2017\/05\/24\/feu-vert-pour-un-nouveau-traitement-anti-cancer_5132830_1650718.html<\/a><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>\u00ab&nbsp;Jusqu\u2019\u00e0 maintenant, la FDA approuvait des th\u00e9rapies contre le cancer en fonction de l\u2019organe touch\u00e9 initialement, comme par exemple le poumon ou le sein&nbsp;\u00bb, a expliqu\u00e9 le docteur Richard Pazdur, directeur par int\u00e9rim des produits h\u00e9matologiques et oncologiques au centre d\u2019\u00e9valuation des m\u00e9dicaments de la FDA. \u00ab&nbsp;Nous avons d\u00e9sormais approuv\u00e9 un traitement sur la base [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-325","post","type-post","status-publish","format-standard","hentry","category-blog"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/posts\/325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/comments?post=325"}],"version-history":[{"count":0,"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/posts\/325\/revisions"}],"wp:attachment":[{"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/media?parent=325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/categories?post=325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.adlington.fr\/index.php\/wp-json\/wp\/v2\/tags?post=325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}